StreetAlpha
13F holdings · Q3 2026

Defilade Capital Management

Emeryville, CA · files as Defilade Capital Management, L.P.
Know the moment Defilade Capital Management filesYou follow Defilade Capital Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 2088557

Defilade Capital Management reported 30 stocks worth $599M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PFE (7.3%), LLY (6.7%) and BMRN (6.0%). Compared with Q2 2026, the fund opened new positions in GILD, AXSM and AMGN, added to ORIC, ASND and COGT, trimmed PFE, LLY and BMRN and sold out of PTCT, BAX and INSM.

Latest filing: what Defilade Capital Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
8 new9 added11 trimmed17 sold outBought about $257M · sold about $431M
New 8
See all 8 →
Added 9
See all 9 →
Trimmed 11
See all 11 →
Sold out 17
See all 17 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$599M−19.8% vs last quarter
Stocks held308 new · 17 sold out
Top 5 weight31.1%spread out
Turnover115%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 4 qtrsHeld
1
PFE
Pfizer Inc
$43.5M7.3%1.5M−247K (−14%)4 of 4
2
LLY
Eli Lilly & Co
$40.2M6.7%35K−4,312 (−11%)4 of 4
3
BMRN
Biomarin Pharmaceutical Inc
$36.1M6.0%602K−80K (−12%)2 of 4
4
GILD
Gilead Sciences Inc
$33.8M5.6%227KNew position1 of 4
5
AXSM
Axsome Therapeutics Inc
$32.3M5.4%175KNew position1 of 4
6
AMGN
Amgen Inc
$31.2M5.2%74KNew position1 of 4
7
ORIC
Oric Pharmaceuticals Inc
$30.6M5.1%2.3M+1.2M (+117%)3 of 4
8
ASND
Ascendis Pharma A/s
$29.4M4.9%129K+34K (+36%)2 of 4
9
ISRG
Intuitive Surgical Inc
$29.2M4.9%72KNew position3 of 4
10
SYK
Stryker Corporation
$22.5M3.8%82KNew position1 of 4
🔒 20 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
PTCT
Ptc Therapeutics Inc
$35.4M434K
BAX
Baxter Intl Inc
$31.1M1.5M
INSM
Insmed Inc
$30M282K
ZBH
Zimmer Biomet Hldgs Inc
$27.3M317K
PODD
Insulet Corp
$26.9M177K

🔒 Free account: see all 17.

Reported value

last 4 quarters
$738MQ4 '25
$712MQ1 '26
$747MQ2 '26
$599MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Defilade Capital Management 13F FAQ

What does Defilade Capital Management own?

Defilade Capital Management reported 30 stocks worth $599M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PFE (7.3%), LLY (6.7%) and BMRN (6.0%). The table above lists every position in the filing (the top 10 without an account).

What did Defilade Capital Management buy and sell in Q3 2026?

Compared with Q2 2026: 8 new positions, 9 added to, 11 trimmed and 17 sold out. New positions include GILD, AXSM and AMGN. It sold all of PTCT, BAX and INSM.

When will Defilade Capital Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Defilade Capital Management's portfolio worth?

The Q3 2026 filing reports $599M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.